吉西他滨联合多烯紫杉醇治疗晚期肺腺鳞癌的临床效果评价

The clinical effect of Gemcitabine combined with Dolitaxel in treatment of advanced lung adenoid squamous carcinoma

目的探讨吉西他滨联合多烯紫杉醇治疗晚期肺腺鳞癌的临床效果。方法选取2013年10月~2017年1月我院收治的92例晚期肺腺鳞癌患者作为研究对象,采用随机数字表法将其分为观察组和对照组,每组各46例。对照组患者给予多烯紫杉醇治疗,观察组患者在此基础上给予吉西他滨进行联合治疗。比较两组患者的治疗效果、平均生存时间(OS)及不良反应发生情况。结果观察组患者的治疗总有效率(91.30%)高于对照组(78.26%),差异有统计学意义(P<0.05)。观察组患者的平均OS为(25.59±4.59)个月,对照组患者的平均OS为(13.49±2.91)个月,观察组患者的平均OS长于对照组,差异有统计学意义(P<0.05)。两组患者的不良反应发生情况比较,差异无统计学意义(P>0.05)。结论吉西他滨联合多烯紫杉醇治疗晚期肺腺鳞癌的临床效果显著,可明显提高患者的生存时间,具有较高的临床应用价值,值得推广。

Objective To explore the clinical effect of Gemcitabine combined with Dolitaxel in the treatment of advanced lung adenoid squamous carcinoma.Methods 92 patients with advanced lung adenocarcinoma treated in our hos- pital from October 2013 to January 2017 were selected as the study subjects,and were randomly divided into observa- tion group and control group according to the random number table method,46 cases in each group.The patients in the control group were treated with Docetaxel,and the patients in the observation group were given Gemcitabine for com- bined treatment on this basis.The treatment effect,average survival time （OS） and adverse reactions were compared be- tween the two groups.Results The treatment of total effective rate of patients in the observation group （91.30%） was lower than that in the control group （78.26%）,and the difference was statistically significant （P〈0.05）.In observation group,the average OS was （25.59±4.59） months,while the average OS in the control group was （13.49±2.91） months,the average OS in the observation was longer than that in the control group,and the difference was statistically significant （P〈0.05）.There was no statistically significant difference in adverse reactions between the two groups （P〉0.05）.Conclusion The clinical effect of Gemcitabine combined with Dolitaxel in the treatment of advanced lung adenoid squamous cell carcinoma is significant,which can obviously improve the survival time of patients and has high clinical application value and is worth promoting.